ECYT Insider Trading Activity and SEC Form 4 Filings
ECYT insider trading summary
No open-market insider purchases or sales of Endocyte Inc (ECYT) have been reported on SEC Form 4 in the past 12 months.
Latest ECYT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 9, 2018 | Michael T. Andriole | Chief Financial Officer | Sell | $10K (635 @ $15.85) |
| Oct 5, 2018 | Beth Taylor | VP Finance & Chief Acctg Offcr | Sell | $109K (7,022 @ $15.56) |
| Oct 5, 2018 | Michael T. Andriole | Chief Financial Officer | Sell | $269K (17,283 @ $15.55) |
| Oct 5, 2018 | Erik C. Chelius | Vice President CMC | Sell | $70K (4,514 @ $15.56) |
| Oct 5, 2018 | Alison A. Armour | Chief Medical Officer | Sell | $142K (9,111 @ $15.56) |
| Oct 5, 2018 | Philip S Low | Chief Science Officer | Sell | $92K (5,928 @ $15.56) |
| Oct 5, 2018 | Christopher P Leamon | Vice President of Research | Sell | $140K (9,028 @ $15.56) |
| Oct 5, 2018 | Michael A. Sherman | President and CEO | Sell | $438K (28,146 @ $15.55) |
| Oct 5, 2018 | Katherine Parker | VP of Human Resources | Sell | $105K (6,771 @ $15.55) |
| Aug 29, 2018 | Christopher P Leamon | Vice President of Research | Sell | $94K (4,696 @ $20.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.